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Pemetrexed (PTX), an antifolate drug, has been approved by the US FDA for first line therapy of 
mesothelioma and non-small cell lung cancer. In addition to its primary site of action on thymidylate 
synthase (TS), PTX also inhibits the second folate-dependent enzyme of purine biosynthesis 
aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART). The accumulation of the 
substrate for AICART, ZMP, in PTX-inhibited cancer cells leads to activation of AMP-activated protein 
kinase (AMPK) with subsequent inhibition of mammalian target of rapamycin (mTOR) and 
hypophosphorylation of its downstream targets responsible for protein synthesis and cell proliferation. 
Inhibitors of mTORC1 like Rapamycin and its analogs (rapalogs) have only partial effects on tumor cells 
as they do not inhibit mTORC2, which phosphorylates Akt subsequently relieving the inhibition of 
 mTORC1, thus leading to poor cytotoxicity by rapalogs. AMPK exerts control on mTORC1 kinase 
activity and PTX mediated activation of AMPK leads to its subsequent downregulation and hence, would 
be expected to have a therapeutic interaction with direct mTOR inhibitors. AZD8055, an ATP-
competitive inhibitor of mTOR kinase, potently inhibits both mTORC1 and mTORC2 and therefore, can 
overcome the feedback mechanism(s) limiting the action of rapalogs to cytostatic effects. To study the 
effects of AMPK activation and mTOR inhibition pharmacologically, we performed growth suppression 
assays using pemetrexed, AICAR, RAD001, and AZD8055. The effect of inhibition of mTOR with these 
drugs was assessed by examining the dephosphorylation of mTORC1 substrates S6K1 and 4E-BP1, as 
single agents and in combination, at their 50% inhibitory concentrations (IC50) by western blotting. Our 
data suggested that AMPK activation via PTX mediated AICART inhibition in combination with direct 
mTOR inhibition by AZD8055 has a synergistic interaction on the proliferation of NSCLC cells in 
culture. Inhibition of mTOR endogenously by pemetrexed, along with direct pharmacological inhibition 
of mTOR prevents the feedback circuit which may compromise the therapeutic efficacy of rapamycin 
analogs. Pemetrexed and AZD8055, as single agents, demonstrated inhibitory activity on phosphorylation 
events of mTORC1 substrates. This activity was markedly increased by combining both the drugs. Our 
findings suggest that direct inhibitors of mTOR enhance the effects of activators of AMPK. These effects 
appear to be mediated via combined effects on mTORC1. Taken together, the combination of catalytic 
site mTOR inhibitors and pemetrexed is a promising therapeutic strategy and calls for further preclinical 
and clinical investigations. 
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Chapter 1: Overview and Introduction 
1.1 Cancer 
 
The World Health Organization (WHO) reports cancer as the leading cause of death, accounting for 8.2 
million deaths worldwide in 2012. (Globocan 2012, IARC). According to the American Cancer Society, 
cancer is the second leading cause of death in the western world, and one in 4 deaths is due to cancer 
(Siegel et al. 2013). Cancer arises when cells in a part of the body start to grow out of control because of 
mutations in genes controlling cell growth and division. Mutations and losses of the tumor suppressor 
genes and/or mutations or overexpression of oncogenes (see below) are the chief causes of cancer. In 
most cases, cancer remains undetected until the tumor has metastasized or spread to other organs in the 
body from its primary site. Thus, there is a need for characterizing biomarkers that can detect the early 
signs of cancer before the disease has progressed far and can still be treated and cured. 
The management of cancer includes several approaches, including surgery, radiation, immunotherapy and 
chemotherapy. Chemotherapy involves a broad range of drugs that attempt to preferentially target the 
rapidly dividing cancer cells and cause cytotoxicity. The ultimate objective is to kill every single cancer 
cell in the body. Traditional cytotoxic anti-cancer drugs often target DNA synthesis or mitosis. As one 
would expect, these drugs can act on normal, rapidly dividing cells and lead to adverse events (Ali and 
Bhattacharya 2014). Recent classes of “targeted” chemotherapeutic agents bind to or downregulate a 
specific protein or complex involved in cancer signaling pathways and inhibit the growth of and/or induce 
cytotoxicity of cancer cells. Because of their specificity, they usually cause less host toxicity (Winkler et 
al. 2014). However, similar to other chemotherapeutics, the therapeutic efficacy of even targeted anti-
cancer compounds is limited by the emergence of resistance and by toxicity profiles. 
Tumors are classified as malignant or benign. Benign tumors are localized, do not spread to or invade 
other tissues and can often be surgically removed. They are not usually considered to be life threatening. 
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Malignant tumors on the other hand have the potential to invade other tissues and metastasize to distant 
sites. Deaths due to cancer are caused principally by metastatic disease.  
1.2  Non-small cell lung cancer 
 
Lung cancer is responsible for 26% and 28% of all female and male cancer deaths, respectively and non-
small cell lung cancer (NSCLC) accounts for 80–85% of lung cancers (Siegel et al. 2013). Smoking is the 
main cause of lung cancer. Treatment therapies were previously based on histological classification of 
NSCLC; however the current paradigm for cancer treatment has shifted emphasis on targeting the 
mutations in the tumor that sustain the tumor phenotype (“driver mutations”). The WHO classifies 
NSCLC into the following subtypes: Squamous cell carcinoma (25%), Adenocarcinoma (40%) and large 
cell carcinoma (10%). There are several other subtypes, like neuroendocrine tumors and carcinomas with 
pleomorphic, sarcomatoid, or sarcomatous elements, but they are present at lower frequencies. Squamous 
cell carcinomas are frequently located centrally in the larger bronchi of the lung and are most frequently 
associated with smoking. Adenocarcinomas, on the other hand, are the most frequently studied lung 
cancers and are further subclassified. They are associated with heterogeneous mutations and are 
aggressive in nature (Brambilla et al. 2001, Heavey et al. 2014).  
A tumor suppressor gene, as the name suggests, is a gene whose protein product protects a cell from 
progressing towards the behavior of a cancerous cell. Alteration or loss of function of these genes is 
harmful and can cause tumors to arise. On the other hand, an oncogene is a gene that has a potential to 
cause cancer; over expression or increased activation of these genes is seen in cancers (Weinberg, Robert 
A (2014) "The Biology of Cancer" Garland Science, page 231). It has been shown that a total of 26 genes 
are frequently mutated in lung adenocarcinomas, of which 10 genes including the  tumor suppressor genes 
p53, CDKN2A and STK11; and several oncogenes like KRAS and EGFR are most frequently mutated 
(Ding et al. 2008). Squamous cell carcinomas also harbor mutations in the p53 gene; however, there are 
additional mutations in genes including, but not limited to, PI3KCA, PTEN, DDR2 and FGFR in 
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Figure 1. Most frequently mutated genes in lung adenocarcinomas 
The X- axis represents the number of somatic mutations in each indicated gene (Y- axis) in 188 tumor and 
normal pairs. Red bars indicate that these genes were found to be significantly mutated by three statistical 
methods (10 genes); blue bars - at least two methods (7 genes); and green bars - one of the three methods 
(9 genes), for up to 26 significantly mutated genes in total. Figure adapted from Ding et al., Nature 455, 
1069 – 1075 (2008) 
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these cancers (D'Arcangelo et al. 2013). Identification of a number of driver mutations in NSCLC and 
other cancers has put an emphasis on tumor biopsies and molecular characterization of tumors, laying the 
foundation for specific targeted therapy.      
1.3  The PI3K – Akt - mTOR pathway 
 
The mTOR (mammalian target of rapamycin) cell signaling pathway is an important central pathway that 
integrates the signals from nutrients and growth factors to regulate cell proliferation and homeostasis in 
most multicellular organisms. Over the last decade, clinical interest has been intensified in the mTOR 
pathway as it has been shown to be dysregulated in diseases such as type 2 diabetes and cancer. [Laplante, 
M. 2009]. The mTOR protein is an evolutionarily conserved, 289-kD serine/ threonine protein kinase that 
belongs to the phosphoinositide 3-kinase (PI3K)-related kinase family. mTOR is a central component of 
two distinct multi-protein complexes named mTOR complex 1 (mTORC1) and 2 (mTORC2) (Fumarola 
et al. 2014).  
mTORC1 consists of at least six proteins: the catalytic subunit, mTOR; the regulatory-associated protein 
of mTOR (Raptor), mLST8 or mammalian lethal with Sec13 protein 8 (also known as GL), PRAS40 or 
proline rich Akt substrate 40 kDa, Deptor or DEP-domain-containing mTOR-interacting protein, and the 
Tti1/Tel2 complex (Laplante and Sabatini 2012). The exact functions of most of the mTORC1 complex 
components are still unclear. Several studies have suggested that the regulatory protein Raptor might play 
a role in the recruitment of substrates for mTOR and regulating assembly and mTORC1 activity (Kim et 
al. 2002, Hara et al. 2002). PRAS40 and Deptor serve as negative regulators of mTORC1. When the 
activity of mTORC1 is reduced, PRAS40 and Deptor are recruited to the complex (Wang et al. 2007), 
where they promote the inhibition of mTORC1. Akt directly phosphorylates PRAS40 and Deptor to 
reduce their physical interaction with the kinase which leads to further activation of mTORC1 signaling 
(Peterson et al. 2009, Wang et al. 2007). The role of mLST8 protein is not yet characterized and in vivo  
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 Figure 2: The mTOR signaling pathway (Andrade-Vieira et al. 2013). LKB1 is also known as STK11 
(see figure 1). It should be noted that mTOR signaling is tightly regulated by a feedback loop via S6K1 
phosphorylation of IRS.  
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deletion of mLST8 does not alter mTORC1 activity (Guertin et al. 2006). Recent findings suggest that the 
novel mTOR binding protein Tti1 along with its binding partner Tel2 play an important role in the mTOR 
activity through maintenance of the complex assembly (Kaizuka et al. 2010). mTORC1 integrates signals 
from the extracellular environment such as growth factors, nutrients and energy sources to regulate cell 
survival, growth and proliferation by stimulating anabolic processes such as lipid and protein 
biosynthesis, and limiting catabolic processes like autophagy (Shimobayashi and Hall 2014).  
The mTOR signaling pathway is much more complex than originally thought and much of its 
understanding has come from the use of a bacterial macrolide Rapamycin. Rapamycin forms a complex 
with the FK506-binding protein of 12 kD (FKBP12) which interacts with the FKBP12- rapamycin 
binding domain (FRB) of mTOR, and leads to inhibition of mTORC1. It is still unclear how the inhibition 
of mTORC1 by FKBP12 takes place but it is speculated that rapamycin allosterically inhibits the kinase 
activity; but it has also been suggested that this is caused by an alteration in the structural integrity of 
mTORC1(Laplante and Sabatini 2012). 
Among the multiple functions of mTORC1, the best-characterized function is regulation of translation. It 
does so via two downstream mediators, the eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-
BP1) and the p70 ribosomal S6 kinase 1 (p70S6K1, S6K1). mTORC1 directly phosphorylates 4E-BP1 
and prevents its binding to the cap-binding protein eIF4E, thus allowing eIF4E to initiate cap-dependent 
translation. The activation of the serine-threonine kinase, S6K1, by direct phosphorylation by mTORC1 
leads to biogenesis of mRNA as well as initiation of translation and elongation and is mediated via direct 
phosphorylation of 40S ribosomal protein S6 by S6K1 (Ma and Blenis 2009). Thus phosphorylation of 
S6K1 by mTORC1 directly stimulates the assembly of the complex needed for cap-dependent 
translational initiation while phosphorylation of 4EBP1 removes an inhibitor of this process. 
The majority of extracellular signals that regulate mTORC1 are transmitted through the key upstream 
heterodimer complex, the tuberous sclerosis 1 (TSC1; or hamartin) and TSC2 (also known as tuberin) 
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proteins, which has a GTPase-activating protein (GAP) domain functioning as a negative regulator of the 
Ras homolog enriched in brain (Rheb). Rheb, in its GTP-bound form, is active at stimulating mTORC1 
activity. Exactly how this activation takes place is yet to be determined but it is thought to be mediated 
via phospholipase D1 interaction with Rheb-GTP (Groenewoud and Zwartkruis 2013). The TSC1/2 
complex negatively regulates mTORC1 activity by stimulating the conversion of Rheb-GTP to Rheb-
GDP resulting in subsequent inhibition of mTORC1. In conditions of energy stress, the TSC1/2 complex 
is activated by the AMP-dependent kinase (AMPK) resulting in mTORC1 inhibition (see section 1.5), 
whereas mitogenic signals inhibit AMPK-mediated TSC1/2 phosphorylation and promote mTORC1 
activity leading to cell growth and proliferation. The TSC1/2 complex serves as an integration node where 
many of the upstream signals converge to regulate mTORC1 activity. The activation of membrane 
receptors, including receptor tyrosine kinases (RTKs) EGFR, VEGFR, HER2, IGFR-1, and PDGFR 
recruits the kinase PI3K to the cell membrane. PI3K phosphorylates phosphatidylinositol lipid substrates 
in the plasma membrane to generate PIP3 from PIP2. PIP3 further recruits and activates a number of 
proteins containing the pleckstrin homology (PH) domain including phosphoinositide-3-kinase-family 
member kinase B/Akt (PKB/Akt) and phosphoinositide-dependent protein kinase-1 (PDK1). PDK1 can 
further phosphorylate Akt and other substrates including serum/glucocorticoid-regulated kinase 1 
(SGK1), and ribosomal S6 kinase 90 kD, polypeptide 1 (RSK1). Phosphorylation of Akt at T308 by 
PDK1 alone does not activate it, but it needs an additional activating phosphorylation from mTORC2 at 
residue Ser473 for full activation (Martinez et al. 2008). Akt in its active form can activate mTORC1 by 
direct inactivating phosphorylations of PRAS40 and TSC2 (Fumarola et al. 2014, Martini et al. 2014). 
The mTOR complex 2 consists of at least seven known components: mTOR, rapamycin-insensitive 
companion of mTOR (Rictor), mammalian stress-activated MAP-kinase interacting protein (mSIN1), and 
protein observed with Rictor 1 and 2 (Protor-1/2), mLST8, Deptor and the Tti/Tel2 complex. Evidence 
suggests that Rictor and mSIN1 stabilize each other to form the structural foundation of mTORC2. Rictor 
also interacts with Protor-1, but the physiological functions of this interaction are not yet established. 
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Similar to its role in mTORC1, Deptor negatively regulates mTORC2 activity and is the only 
characterized endogenous inhibitor of mTORC2 so far discovered. In contrast to its role in mTORC1, 
mLST8 is essential for mTORC2 function; knockout of this protein severely alters the stability and the 
activity of this complex. Much less is known about mTORC2 compared to mTORC1. However, recent 
studies have demonstrated that mTORC2 is a key mediator in several biological processes such as cell 
growth and proliferation, the function of the cytoskeleton machinery, and metabolism (Laplante and 
Sabatini 2009).  
Although mTORC2 is insensitive to rapamycin, prolonged exposure to rapamycin or its analogs 
suppresses mTORC2 activity by disturbing the assembly of this complex. mTORC2 does not directly 
respond to signals from nutrients, but studies have shown that mTORC2 can be activated by growth 
receptors like the insulin receptors by a PI3K mediated pathway whose mechanism is not clear. The 
absolute necessity of ribosomes for the activation of mTORC2 (Zinzalla et al. 2011) suggests that the 
PI3K related pathway could be ribosome-dependent. mTORC2 phosphorylates Akt at Ser473 which 
results in complete activation of Akt; lack of Akt phosphorylation by mTORC2 impedes phosphorylation 
of some Akt substrates like Forkhead Box O1/3a (FoxO1/3a) but not TSC2 and GSK3. mTORC2 also 
directly activates serum- and glucocorticoid-induced protein kinase 1 (SGK1) that regulates ion transport 
and growth. It also phosphorylates a third protein kinase Cα (PKCα) and other effectors like paxillin and 
Rho- and Rac–GTPases to control the actin cytoskeleton.(Laplante and Sabatini 2012). Despite the 
advances in the mTOR field, the understanding of mTORC2 is limited and additional work is needed to 
evaluate the biological functions of mTORC2 and its interaction with mTORC1. 
1.4  Feedback circuit controlling signaling to mTORC1  
 
The mTOR pathway is subject to very tight regulation via several positive and negative loops. One of the 
best characterized loops is a S6K1 mediated negative feedback on PI3K. S6K1 phosphorylates a growth 
factor receptor adaptor protein IRS-1, to inhibit it and induce its degradation, which dampens the PI3K – 
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Akt pathway (see Figure 2). The importance of this feedback became clear from the reactivation of 
signaling to mTORC1 following rapamycin-induced inhibition of S6K1 phosphorylation (O'Reilly et al. 
2006). mTORC1, specifically, is regulated by a positive feedback through mTORC2 which 
phosphorylates Akt to reinforce Akt/mTORC1 signaling. These positive and negative feedback loops 
have a crucial importance clinically as responses to mTOR inhibitors are currently thought to be limited 
by their operation. 
1.5  LKB1- AMPK - mTOR Signaling Pathway 
 
AMPK is a sensor molecule of cellular energy status that maintains cellular energy homeostasis, and is 
thought to have evolved in the cellular response to energy stress (Hardie 2011). It also has distinct roles in 
mitochondrial biogenesis and disposal, autophagy, and cell growth and proliferation. It senses an increase 
in cellular AMP: ATP ratio and is activated by metabolic stresses that inhibit ATP production or 
accelerate ATP consumption (Hardie 2011). Upon activation, AMPK regulates several downstream 
processes that inhibit cell growth and proliferation. AMPK comprises of three subunits: the catalytic α 
subunit, the structural scaffold β subunit, and the regulatory γ subunit. The α subunit contains the kinase 
domain with a conserved threonine residue at codon 172 that is phosphorylated by the upstream kinases in 
the activation loop (Hardie 2011). The binding of AMP (or AMP-mimetic ZMP) causes a conformational 
change in the γ subunit of AMPK that leads to the phosphorylation of the α subunit at T172. This 
phosphorylation is crucial for the activity of AMPK. The main upstream kinase that phosphorylates 
AMPK at T172 is a serine/threonine kinase LKB1 (Liver kinase B1or STK11). The discovery of LKB1 
first introduced the connection between AMPK and cancer. LKB1 was originally discovered as a tumor 
suppressor gene responsible for an inherited susceptibility to cancer, the Peutz-Jeghers syndrome, and 
now is found to be mutated in almost 30% of NSCLC (Han et al. 2013). LKB1 is active as a 
heterotrimeric complex (see Figure 2). It is unclear if the tumor suppressor functions of LKB1 are 
mediated via AMPK because, in addition to AMPK, LKB1 activates another 12 AMPK-related kinases 
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whose functions are poorly defined (Shackelford and Shaw 2009). The effects of AMPK in regulating cell 
growth and proliferation have been extensively studied. Once activated, AMPK causes p53 dependent cell 
cycle arrest by inhibiting major biosynthetic pathways responsible for synthesis of fatty acids, 
phospholipids, proteins, and ribosomal RNA. AMPK T172 can also be phosphorylated by CAMKKβ in 
the presence of Ca
+2
 or a calcium ionophore, but absence of AMP. In conditions of stress, AMPK 
regulates cellular processes by acting on mTORC1 signaling with a dual mechanism that inhibits 
mTORC1 activity via direct phosphorylation of TSC2 and of Raptor (Inoki et al. 2003). AMPK 
phosphorylation of TSC2 activates the conversion of Rheb-GTP to Rheb-GDP leading to subsequent 
inhibition of mTORC1. Phosphorylation of Raptor at two conserved serine residues causes to 
downregulation of mTORC1 activity (Gwinn et al. 2008).  
AMPK is also a direct regulator of autophagy (Hoyer-Hansen and Jaattela 2007). Autophagy is a cellular 
process of engulfment of cytoplasmic components that are dysfunctional or in surplus by vacuoles which 
fuse with lysosomes to form autophagosomes. This process is of importance during cellular starvation as 
a means to recycle amino acids for the conservation of vital proteins (Hardie 2011). It also has 
implications in cancer biology and serves to prevent accumulation of damaged organelles and proteins. 
AMPK, under glucose starvation, phosphorylates UNC-51-like kinases 1/2 (ULK1/ULK2) – the protein 
kinases located at the top of the autophagy cascade promoting autophagosome formation and autophagy. 
In the absence of AMPK mediated mTORC1 inhibition, mTORC1 1 phosphorylates ULK1 at multiple 
sites to prevent its interaction with AMPK and thus inhibits autophagy (Fumarola et al. 2014). 
1.6  Current chemotherapy for NSCLC 
 
Treatment for NSCLC is based mainly on the stage of the cancer and how far it has spread. Generally, 
early stage cancer does not invade other tissues and is localized at the primary site. It is most often treated 
by surgery alone, and does not require radiation or chemotherapy. In some cases though, radiation or 
chemotherapeutic intervention is required in order to kill residual tumor cells left by surgery. Stage 1 and 
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stage 2 NSCLCs are still localized, and are treated by surgery, radiation, chemotherapy or a combination 
of these methods. Stage 3 – 4 NSCLC is considered to have spread extensively to several lymph nodes or 
to have metastasized and invaded other tissues. Treatment options in such cases depends on patients 
overall health, size of tumor, the extent of spread and how well an individual can tolerate a particular 
treatment. Stage 4 tumors are widely spread when diagnosed, and are very hard to cure. Therapeutic 
interventions may prolong the life of the individuals and relieve symptoms, but aren’t likely to result in 
cures of advanced stage NSCLC (Ettinger et al. 2012). 
The first line of chemotherapeutic treatment for NSCLC is platinum based therapy with overall response 
rate of 25%-35% and median survival of 8-10 months (Kawabata et al. 2014). Unfortunately, this effect 
plateaus off. Several studies have combined cisplatin, carboplatin and oxaliplatin with targeted 
compounds like bevacizumab (Peters et al. 2012). However, the usage of these combinations is limited to 
certain genotype and also has severe toxicity profiles. The best chemotherapy regimen for advanced 
NSCLC still remains unclear. The US Food and Drug Administration approved pemetrexed for the 
treatment of pleural mesothelioma in 2004. Pemetrexed in combination with cisplatin was approved for 
first-line treatment of NSCLC in 2008 (Scagliotti et al. 2008), and, notably, for maintenance therapy of 
NSCLC in 2009, the first drug ever approved for this purpose (Owonikoko et al. 2010). PTX inhibits 
thymidylate synthase (Taylor et al. 1992, Shieh et al. 1998) but also has a second mechanism:  activation 
of the AMP-dependent protein kinase (AMPK) via inhibition of AICART (Racanelli et al. 2009). 
Monotherapy has not been much effective in treating NSCLC and, when pemetrexed alone was compared 
to carboplatin and pemetrexed in population of 217 patients, the combination therapy demonstrated higher 
therapeutic efficacy over the single agent (Peters et al. 2012). 
Recent approaches to treat NSCLC use targeted agents. In NSCLC with EGFR mutations, tyrosine kinase 
inhibitors (TKIs) are prescribed as first-line agents (Zhou et al. 2011). Studies have shown that erlotinib 
(Tarceva) helps to control certain lung tumors, especially in women and in people who have never 
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smoked. Cetuximab is another drug that targets EGFR. In patients harboring mutations in the ALK gene, 
crizotinib (Xalkori) can shrink tumors and has been shown to provide good outcomes (cancer.org).  
1.7  Activators of AMPK 
  
A fundamental trait of all multicellular eukaryotic cells is that they integrate the signals from nutrients 
and growth factors to drive cell proliferation and growth, only when the supply of nutrients is sufficient 
and cell division can be successfully completed. The signals from the energy stores and nutrients are 
transmitted via a sensor molecule AMPK, which is activated when intracellular levels of ATP decline and 
that of AMP rise. Activation of AMPK by increase in the levels of AMP is a signal that cellular energy 
stores are depleted and cell proliferation has to stop. LKB1 phosphorylates the AMPK activation loop on 
AMPKα in conditions of energy stress and controls cell growth and proliferation via effects directly on 
mTORC1; mTORC1 being one of the major mediators of cell growth and proliferation. Thus, one would 
expect that activation of AMPK can be explored as one of the potential mechanisms to inhibit cell 
proliferation and survival, a desirable strategy for the treatment of cancer. 
Given its role in metabolic physiology, AMPK has garnered interest as a target for the treatment of type 2 
diabetes and other metabolic diseases such as obesity, cardiovascular disease and fatty liver disease. 
AMPK regulates glucose homeostasis by balancing glucose uptake and production (Kurth-Kraczek et al. 
1999). It promotes glucose uptake by stimulating glucose transporter 4 (GLUT4) to translocate from 
intracellular storage vesicle to the plasma membrane, an effect thought to be mediated via Rab GTPase-
activating protein AS160 and TBC1D1. The AMPK activator, 5-amino-4-imidazolecarboxamide 
ribonucleoside (AICAR), has been shown to increase glucose uptake and translocation of GLUT4 to 
plasma membranes in skeletal muscle of rat (Lin et al. 2014). Metformin and thiazolidinedione’s, which 
are type 2 anti-diabetic drugs, inhibit hepatic gluconeogenesis by activation of AMPK, thereby 
downregulating expression of gluconeogenic genes such as phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (G6Pase) (Lin et al. 2014).  
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At least 33 AMPK activators have been identified so far (Lin, Chen et al. 2014). Metformin, phenformin, 
and AICAR have been shown to activate AMPK and suppress growth of tumor cells in culture and in 
rodent cancer model xenografts. It has been shown that diabetics treated with metformin, which indirectly 
activates AMPK, had a lower incidence of cancer than patients on other anti-diabetic therapies and studies 
are being done to examine the effect of Metformin on cancer incidence (Han et al. 2013). AICAR is 
directly converted to aminoimidazolecarboxamide ribonucleotide (ZMP) – an AMP mimetic, via 
adenosine kinase, and the accumulating ZMP activates AMPK to control cell growth and inhibit 
proliferation through mTORC1inhibition (Racanelli et al. 2009). In this laboratory, Rothbart et al (2010) 
have shown that pemetrexed, an anti-folate, indirectly activates AMPK in human carcinomas. They 
showed that pemetrexed inhibits the second folate-dependent enzyme of de novo purine synthesis, 
aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART) in human leukemic cells. 
Inhibition of AICART leads to accumulation of its substrate ZMP which in turn activates AMPK 
(Racanelli et al. 2009, Rothbart et al. 2010). 
Current evidence suggests that AMPK activation inhibits major biosynthetic pathways in the cells and 
controls cell survival, growth, and proliferation. These effects enforce a metabolic checkpoint on the cell 
cycle suggesting that AMPK activators deserve further investigation as cancer therapeutics (Jones et al. 
2005). However, a study by Huang et al. (2008) showed that although AMPK activators delayed 
tumorigenesis, all of the mice eventually developed tumors. One plausible explanation to explain how 
tumor cells escape the cytostatic effects of AMPK activators could be that they acquire additional 
mutations, e.g.: loss of the LKB1 gene that prevents continued AMPK activation (Sanchez-Cespedes et al. 
2002). This suggests that AMPK activators are likely to be most effective when used in combination with 
other targeted therapeutics.  
An important fact to note here is the existence of an energy associated growth suppressor pathway 
mediated by AMPK capable of suppressing cancer growth and, possibly, its development. This point outs 
that diet and exercise might be correlated with cancer incidence rates; and it has been suggested that  
14 
 
 
                                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structures of rapamycin and its analogs: Rapamycin (A), temsirolimus (B), everolimus 
(RAD001; C), and ridaforolimus (D). 
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dietary factors might contribute to an estimated one-third of all cancer deaths (Martinez et al. 2008). It has 
been seen from a number of epidemiologic studies that cancer risk is higher amongst people with 
metabolic syndrome, or obesity, or type 2 diabetes. A recent study has shown that AMPK was activated 
and mTORC1 signaling was suppressed in rodent tissues in a dose-dependent manner by increasing the 
levels of dietary restriction (Shaw 2009).  
Taken together, activation of AMPK- either directly or indirectly by PTX-mediated AICART inhibition 
regulates mTORC1 function along with other important cellular processes. These processes are most 
frequently deregulated in cancer, prompting studies to evaluate the anti-tumor effects of activators of 
AMPK. 
1.8  mTOR inhibitors 
 
1.8.1 First generation mTOR inhibitors: Rapamycin and its analogs 
The first mTOR inhibitor to be discovered was rapamycin, a macrolide antibiotic produced by 
Streptomyces hygroscopicus. Rapamycin strongly inhibits T-cell proliferation and was approved by FDA 
in 1999 as an immunosuppressant to prevent organ transplant rejection (Sehgal 2003). Rapamycin 
allosterically inhibits mTORC1 through the FRB domain (see section 1.3) while mTORC2 is insensitive 
to rapamycin. It has been shown that rapamycin acts by blocking G1 cell cycle progression (Sehgal 2003). 
Several studies have also shown that rapamycin induces apoptosis through inhibition of hypoxia-induced 
increases in hypoxia-inducible factor 1α (HIF-1α) (Houghton 2010). It also induces autophagy and 
enhances radiation therapy when combined with a Bcl-2 inhibitor that concurrently induces apoptosis 
(Fumarola et al. 2014). However, the effects of rapamycin are generally confined to a cytostatic effect and 
the clinical use of rapamycin as an anti-tumor agent is limited (Guertin and Sabatini 2009). This 
therapeutic limitation is thought to be because of its inability to inhibit mTORC2, and the activation of 
Akt kinase following initial inhibition of mTORC1. Inhibition of mTORC1 results in feedback induction 
of IRS-1 expression and activation of IGF-I signaling; thus reducing the antitumor effects of mTORC1  
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Figure 4: Structures of second generation mTOR inhibitors: OSI-027 (A), INK-128 (B), PP-242 (C), 
KU0063794 (D), Torin (E), XL-388 (F), and AZD8055 (G). 
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inhibitors (O'Reilly et al. 2006) (see Figure 2). Rapamycin treatment induces IRS-1 expression due to 
inhibition of p70-S6K1 phosphorylation, which results in increased IGF-IR/IRS-1/PI3K signaling to Akt. 
Reports have shown that p70- S6K mediates phosphorylation of IRS-1 inhibitory serine sites (Ser312 
and/or Ser636/639) which lead to IRS-1 degradation (Manning 2004). Thus, suppression of p70-S6K1 
activity by rapamycin may prevent inhibitory IRS-1 phosphorylation, thereby stabilizing IRS-1. An 
increase in IRS-1 adapter protein levels is thought to induce Akt activity by augmenting IGF-IR signaling 
to PI3K/Akt (Shi et al. 2005). Hence, combining rapamycin with inhibitors of IGF-IR or Akt seems to be 
a good therapeutic strategy and this approach is under investigation (Wan et al. 2007). Currently, 
rapamycin is only active against certain tumors such as mantle cell lymphoma, renal cell carcinoma and 
endometrial cancer, in which it is thought to block the effects of mTORC2 by some unexplained 
mechanism (Liu et al. 2009).  
Owing to poor water solubility, Rapamycin has a low bioavailability. Hence, several analogs of 
rapamycin with better pharmacokinetic profiles, collectively called “rapalogs”, have been developed. 
They include Everolimus (RAD001/Affinitor), Temsirolimus (Toricel) and Ridaforolimus (MK-8669) 
(Figure 3); all of these analogs appear to have the same mechanism of action as rapamycin. Everolimus, 
originally commercialized as an immunosuppressant, was recently approved for the treatment of 
advanced renal carcinoma by the US FDA. A recent study has demonstrated that, in addition to mTORC1 
inhibition, everolimus inhibits the response of vascular endothelial cells to stimulation by vascular 
endothelial growth factor (VEGF) and that its anti-tumor effects are attributed to its anti-angiogenic 
properties (Houghton 2010). Temsirolimus is a prodrug of rapamycin and is converted to rapamycin in 
vivo. Ridaforolimus is still under phase III clinical trials for a variety of cancers that include advanced 
malignancies such as metastatic soft tissue and bone sarcoma, breast cancer, and relapsed hematological 
malignancies (Liu et al. 2009).  
Rapalogs, like rapamycin, have shown significant activity in clinical trials but their activity is also limited 
to inhibition of mTORC1. The rapalogs exhibit a cytostatic effect on tumor growth suppression and 
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cancer disease stabilization, rather than regression (Meric-Bernstam and Gonzalez-Angulo 2009). To 
circumvent this, they have been combined with other chemotherapeutic agents and better therapeutic 
efficacies have been observed with combinations over single drug treatment. For instance, the 
combination of antiestrogen ERA-923 with temsirolimus has been reported for treating breast cancer 
(Sadler et al. 2006). Rapalogs are also been combined with Insulin-like growth factor I receptor (IGF-IR) 
inhibitors because of the rapalog-induced Akt activation (feedback loop) observed in cancer cell lines in 
vitro and in clinical trials (Shi et al. 2005, O'Reilly et al. 2006). Other studies have reported the evaluation 
of combination of rapalogs with PI3K inhibitors NVP-BKM120 and XL-765 (SAR245409), the Akt 
inhibitors like GSK690693 and Perifosine, inhibitors of the RAS/RAF/MEK pathway, and other targeted 
agents. Each of these combinations has been shown to enhance therapeutic efficacy in preclinical models 
(Liu et al. 2009). 
1.8.2 Second generation mTOR inhibitors: Catalytic site (ATP-competitive) inhibitors 
Despite the preclinical promise shown by rapalogs, the clinical utility for rapalogs has been limited to a 
few cancers. Tumor relapse is often observed with rapalogs due to their selectivity for mTORC1 
inhibition and the effect of the negative feedback loop on IRS-1. Although they cause a marked 
hypophosphorylation of S6K1, rapalogs fail to sustain the dephosphorylation and inhibition of 4EBP1, 
and cell proliferation persists even in the presence of the drug (Fumarola et al. 2014). Interestingly, 
rapalogs exhibit strong inhibitory activity towards one mTORC1 substrate S6K1, while inhibition of 4E-
BP1 is minimal, indicating that it could be an important mechanism of drug resistance. In order to 
overcome these limitations, novel dual mTORC1/2 inhibitors have been developed and are being studied 
extensively. These compounds (Figure 4) bind to the catalytic domain of mTOR, and inhibit the mTOR 
kinase activity, thus effectively inhibiting both mTORC1 and mTORC2 (Chresta et al. 2010). The 
inhibition of mTORC2 is thought to prevent feedback induction of Akt (Hsieh et al. 2012). These ATP-
competitive inhibitors are highly potent at inhibiting mTORC1 and mTORC2 such that they exhibit 
inhibitory concentrations (IC50) in vitro in the low nanomolar range as determined by S6K1 
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phosphorylation at T389 and Akt phosphorylation at S473, respectively. They are also very selective such 
that structurally related kinases are inhibited only at much higher concentrations of drug (Guertin, and 
Sabatini 2009).  
Torin 1 was one of the first dual mTORC1/2 inhibitor developed. It is shown to inhibit proliferation of 
primary tumor cells to a greater extent than rapamycin (Liu et al. 2009). Shokat and his colleagues have 
developed PP242 and PP30, both ATP-site mTOR inhibitors exhibiting similar therapeutic profiles to that 
of Torin1 (Liu et al. 2009). It was assumed that these drugs presented greater therapeutic efficacies than 
rapalogs because of their ability to inhibit both mTORC1 and mTORC2. Interestingly, it was observed 
that, in addition to mTORC2 inhibition, the anti-tumor effects of  PP242 and PP30 are mediated via more-
complete inhibition of mTORC1 leading to sustained dephosphorylation and inhibition of 4EBP1 and 
cap-dependent mRNA translation (Feldman et al. 2009). A number of mTOR catalytic site inhibitors are 
under preclinical and phase I/II trials and have shown remarkable potency and selectivity for mTORC1 
and mTORC2 (Liu et al. 2009). These include KU0063794 (AstraZeneca), INK-128, XL388, OSI-027 
and AZD8055. These compounds are under investigation for NSCLC and have demonstrated superior 
efficacies compared to rapamycin and its analogs in preclinical testing (Liu et al. 2009, Guertin and 
Sabatini 2009, Fumarola et al. 2014, Hsieh et al. 2012).  
AZD8055 is a particularly interesting member of this family of drugs. It is an orally bioavailable, potent, 
and selective mTOR kinase inhibitor with excellent selectivity for these kinases and modest activity 
against all class I PI3K isoforms and other members of the PI3K-like kinase family. AZD8055 has shown 
proven efficacy in NSCLC cell lines superior to that of rapamycin (Guertin and Sabatini 2009). AZD8055 
has been shown to significantly decrease the phosphorylation of 4EBP1 on the rapamycin-insensitive 
T37/46 sites and to potently inhibit cap-dependent translation at low nanomolar concentrations with 
concomitant inhibition of cell proliferation. It is also thought to promote a greater autophagosome 
formation and autophagy activation than rapamycin. In addition, AZD8055 induced significant growth 
inhibition and regression in NSCLC xenografts (Fumarola et al. 2014). Similar to the rapalogs, catalytic 
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site mTOR inhibitors have also been combined with inhibitors of the PI3K-Akt pathway to overcome the 
negative feedback of mTORC1 inhibition on PI3K/Akt and MAPK signaling (Liu et al. 2009, Guertin and 
Sabatini 2009). AZD8055, in combination with MEK 1/2 inhibitor AZD6244 (selumetinib) has 
demonstrated superior anti-tumor efficacy over either drug given as single agents (Fumarola et al. 2014).  
Some ATP- competitive inhibitors show dual activity against mTORC1/2 as well as activity against the 
p110 subunit of PI3K due to the structural similarity of the catalytic domains of these proteins, and are 
called dual mTOR-PI3K inhibitors. These agents have the potential of completely shutting down the 
PI3K/Akt/mTOR pathway but it may cause greater toxicity. Examples of this class of drugs are NVP-
BEZ235 and XL-765 (SAR245409); these compounds are currently under phase I/II clinical trials for 
NSCLC and breast cancer (Liu et al. 2009, Fumarola et al. 2014). 
1.9  Combination therapy for cancer 
 
Combination therapy refers to the use of more than one drug at a time for treating a disease. As often 
observed with other chemotherapies, most cancers become resistant to one drug and the clinical response 
declines or stops. Most often an initial responsive tumor becomes refractory and starts growing again over 
a period of time. This is thought to be attributed to inherent resistance of the tumor cells due to pre-
existing mutations. Under typical conditions, a tumor mass of 10
9
 cells has 1000-10000 inherently 
resistant cells which have the potential to repopulate and bring about a recurrence of tumor. Under such 
conditions, there is a great need for multidrug therapy. The rationale for combination therapy is to use 
drugs that act on different targets and by different mechanisms to manage the heterogeneity of cancer 
cells, thereby decreasing the likelihood of developing resistant cancer cells. Another benefit of using 
combination therapy is that each drug can be given at lower concentrations than as single agents, thus 
reducing events of toxicity.  
A tumor is a population of cells that have undergone genetic alterations and have gained capacity to grow 
and proliferate uncontrollably. These genetic mutations are most often observed in the signaling pathways 
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that control cellular survival in response to nutrients and energy. Aberrations in one or more proteins that 
control growth and homeostasis, belonging to different signaling pathways leads to continuous signaling 
inputs, thereby causing tumors to arise. Heterogeneity among tumor cells increases the number and 
diversity of potential target sites for chemotherapy and the need for combining therapeutic agents. The 
main aim of a combination therapy is to achieve increased therapeutic efficacy with a combination of 
drugs over that achievable with the individual agents, providing selective synergism against the tumor, 
and to minimize outgrowth of drug-resistant tumor clones.  
1.10 Hypothesis 
 
The PI3K-Akt-mTOR cell signaling pathway transmits signals from nutrients and controls cell survival 
and growth. On the other hand, the LKB1-AMPK-mTOR axis of the mTOR pathway recognizes cellular 
energy levels and responds to energy stress to regulate cell growth and proliferation. Thus, the PI3K-Akt-
mTOR and LKB1-AMPK-mTOR axes, that are crucial for cell survival and growth mechanisms, 
converge on the mTOR protein which has been validated as a promising target for cancer therapy. An 
activator of AMPK, pemetrexed, is approved as a first line drug in combination with cisplatin for the 
treatment of NSCLC. Pemetrexed exerts its effects via a) inhibition of TS, and b) AMPK mediated 
mTORC1 inhibition. Studies have showed that the combination of pemetrexed with targeted agents such 
as bevacizumab have shown better therapeutic profiles over the single agents. Rapamycin and its analogs 
inhibit mTORC1 activity and have emerged as first generation mTOR inhibitors. RAD001 is FDA 
approved in renal cell cancer. However, due to their inhibitory effect on mTORC1, they have shown a 
more modest clinical response than expected. A newer generation of mTOR antagonists known as 
“catalytic site” mTOR inhibitors, target both mTORC1/2 and are expected to have superior efficacy than 
the rapalogs. They are currently under phase I/II clinical trials. We proposed to experimentally determine 
whether an AICART inhibitor (AMPK activator) would enhance the activity of direct mTOR inhibitors 
and vice-versa. We hypothesized that the dual mTOR antagonists, which inhibit the ATP-site of 
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mTORC1/2, would have an additive or synergistic interaction with an activator of AMPK, which 
endogenously inhibits mTORC1 signaling through TSC1/2 and raptor phosphorylation. Dual mTOR 
inhibitors would control the feedback loops that regulate mTOR activity and thereby suppress the PI3K-
Akt-mTOR signaling, whereas an AMPK activator (Pemetrexed) would regulate endogenous growth 
signals through mTORC1 inhibition. Combining the two effects is a promising strategy in order to 
achieve anti-cancer activity. 
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Chapter 2: Materials and Methods 
 
2.1 Cell lines, chemicals and reagents 
NSCLC cell lines H661, H441 and H358 were purchased from American Type Culture Collection 
(Manassas, VA) and kept under liquid nitrogen in 10% DMSO (Sigma Chemicals, St. Louis, MO) and 
90% Fetal Bovine Serum (FBS; Atlanta Biologicals) until use. Pemetrexed disodium (LY231514)  was 
obtained from Eli Lilly and Company (Indianapolis, IN)  and a stock solution of 1 mM was prepared by 
dissolving 5.16 mg PTX in 10 ml 1X phosphate buffered saline (PBS, Cat #10010, pH 7.4; Gibco, Life 
Technologies, NY, USA). AICAR (Cat #A611700) was obtained from Toronto Research Biochemicals 
(North York, Ontario, Canada) and a stock solution of 40 mM was prepared by dissolving 103.2 mg of 
AICAR in 10 ml 1X PBS. RAD001(Cat # S1120; Everolimus; Novartis) and AZD8055 (Cat # S1555; 
AstraZeneca), were purchased from Selleck Chemicals and were dissolved in dimethyl sulfoxide (DMSO) 
as stock solutions at 20mM and 10 mM, respectively. All drug stock solutions were stored at -20⁰C until 
use. Stock solutions of thymidine (560 μM) were routinely made by dissolving 0.00678 g of thymidine 
powder in 48 ml of 1X PBS. The concentration was determined by measuring absorbance at 267 nm from 
a 1:10 dilution of the stock solution in 1X PBS using an extinction coefficient of 9.7 mM
-1
 cm
-1
. The 
volume was adjusted accordingly with 1X PBS for a final concentration of 560 μM. This solution was 
filter-sterilized and was stored at -20°C. Unless otherwise noted, thymidine was typically used at a final 
concentration of 5.6 µmol/L in rescue experiments. Complete EDTA-free Protease Inhibitor Cocktail 
tablets (Cat #11873580001) were from Roche Applied Science (Indianapolis, IN). Bio-Rad dye 
concentrate (Cat # 500-0006), 30% Acrylamide/BIS solution 37.5:1 (Cat #1610158), Laemmli Sample 
Buffer (Cat #1610737), and Dual Color Precision plus Protein Standard (Cat #1610374) were from Bio- 
Rad Laboratories. Immobilon polyvinylidene fluoride (PVDF) membrane (Cat #IPVH00010) was from 
Millipore (Billerica, MA). StartingBlock Blocking Buffer (Cat #37542), goat anti-rabbit IgG (Cat 
#31462), and goat anti-mouse IgG (Cat #31348) secondary antibodies were from Thermo Scientific. A list 
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of antibodies and their sources can be found in Table 1. All other reagents were from Fisher Scientific 
(Waltham, MA) or Sigma Aldrich (St. Louis, MO) and were of the highest available purity. 
2.2 Cell Culture  
 
Cells were grown from frozen stock in RPMI 1640 (Cat #11875, Life Technologies, NY, USA) 
supplemented with 10% FBS. Cells were cultured in T75 flasks (CellStar) and were maintained at 5% 
CO2 in a humidified incubator at 37⁰C. Cells were passaged when at 80% confluence after washing once 
with 1X PBS; they were detached with 0.25% Trypsin-EDTA (Cat #15400 Gibco/Invitrogen, 0.53mM 
EDTA- 4Na) for 4-5 minutes and the trypsin was then deactivated with RPMI 1640 medium containing 
FBS. Cells were collected and centrifuged at 4000 rpm for 5 minutes (Centrifuge 5810 R G18.0). Medium 
was aspirated and fresh medium was added to the cell pellet. Cells were suspended in the media and 1 ml 
of cell suspension was added in T75 flask with 10ml RPMI 1640 medium. Cells were plated and allowed 
to adhere to the plate overnight under incubation. All plates with cells were examined for bacterial and 
fungal infections prior to experiments. Experiments were performed within 10-12 passages of cells from 
frozen stock. Cells were discarded after 12 passages and a new frozen vial was thawed.  
2.3 Cellular growth suppression assay for single drugs 
 
NSCLC cells were seeded at a density of 20,000 cells/well in a 12-well plate in RPMI 1640 media 
supplemented with 10% FBS and allowed to adhere for 48 hours. This time point was defined as T0 h. 
Conditions were plated in duplicate. Fresh media containing graded concentrations of drugs were added 
after 48 hours. Whenever PTX was used in the treatment, the medium used was RPMI 1640 
supplemented with 10% dFBS. Experiments typically lasted for 72 hours after drug treatment. Following 
the incubation period, cells were washed with 1X PBS, trypsinized in 1.5 ml 1x trypsin-EDTA, and 1 ml 
of a single-cell suspension was counted electronically using a Z1 Coulter Particle Counter (Figure 3; 
Beckman Coulter, Brea, CA). Data were analyzed using Microsoft Excel 2010 (Microsoft Inc.,  
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Figure 5: Schematic representation of cellular growth suppression assays in a 12-well plate. 
Cells were seeded in 12-well plates at a density of 20000 cells per well. After allowing cells to adhere for 
48 hours, media was replaced with fresh media containing indicated drugs. After 72 hours following drug 
treatment, media was aspirated and cells were counted using a Beckman Coulter counter. 
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Redmond, WA), and SigmaPlot version 12.3 software (Systat Software Inc, San Jose, CA). Data is 
presented as percent cell growth of experimental samples relative to controls in the absence of drug. Data 
are expressed as the mean ± SD. 
2.4 Cellular growth suppression assay for combinations of drugs: Design and 
treatment 
 
H358 cells were plated and allowed to adhere as mentioned in section 2.3. Fresh media containing graded 
concentrations of single drugs (Drug A, Drug B) and combination of two drugs (Drugs A+B) were added 
after 48 hours (T0 h), as discussed below. The rest of the experimental protocol and analysis was done as 
in section 2.3.  
The combination drug treatment protocol was as follows: 
In order to study the combined effects of two drugs, data were needed from individual drug treatment at 
the same time as the combination treatment was performed. Hence, in every combination study, 
individual drug dose-response was also conducted as in section 2.3. For the combination treatment wells, 
the following experimental design was used (also see Figure 6). 
Drug A: graded concentrations (e.g.: PTX = 0, 10, 32, 100, 320, 1000, 3000, 10000 nM) 
Drug B: graded concentrations (e.g.: AZD8055 = 0, 10, 32, 64, 100, 320, 1000 nM) 
Fresh media containing drug A was put on the cells followed by addition of drug B solution immediately. 
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Figure 6: Design of combination drug experiments in a 12-well plate. 
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2.5 Evaluation of combined effects 
 
Data obtained from the combination experiments were analyzed using Microsoft Excel 2010 (Microsoft, 
Redmond, WA), and SigmaPlot version 12.3 software (Systat Software Inc, San Jose, CA). Each 
combination dose range was plotted as a single curve on a multiple line graph to measure the shift in the 
dose-response curve. Data is presented as percent cell growth of experimental samples relative to controls 
in the absence of drug.  
2.5.1 TC Chou method for calculation of IC50 and combination index 
CI is a quantitative measure of the degree of drug interaction in terms of synergism (CI < 1), additive 
effect (CI = 1), or antagonism (CI > 1) for a given combination treatment. Inhibitory concentration 50 
(IC50) and Combination Indices (CIs) were calculated using CompuSyn software program (ComboSyn, 
Inc., Paramus, NJ, USA). Affected fraction (Fa) is defined as a function of effect level (e.g., degree of 
inhibition) by a dose of drug. Fa values were calculated according to the program’s instruction as follows: 
[(100 - % growth value)/100] (Chou 2010). 
2.5.2 Isobolograms 
 
An isobologram is a graphical representation of drug interactions and is considered as a “gold standard” 
for the assessment of drug combinations (Chou 2010). The construction of isobolograms was done using 
normalized IC50 values of compound A alone and in the presence of graded concentrations of compound 
B, and normalized IC50 values of compound B alone and in the presence of graded concentrations of 
compound A. The fractional values of the individual IC50 of compound A and B needed to affect a 50% 
inhibition were then plotted on the x and y axes respectively. A typical isobologram consists of a line of 
additivity, which is a line joining the IC50s of both the compounds on x and y axes. If the combination 
drugs data falls on the line of additivity, the drug interaction is called additive. If the data lies above or 
below the line of additivity, the drug interaction is called antagonistic or synergistic, respectively. A 
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typical isobologram can be interpreted as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: A schematic representation of an isobologram. 
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2.6 Immunoblotting  
 
Total Protein Isolation: Protein was typically harvested from 2-5 x 10
6
 cells grown on 100 mm dishes 
(CytoOne). Prior to total protein harvest, one protease inhibitor cocktail tablet was dissolved in 25 ml 1X 
PBS and placed on ice.  Tissue culture plates were kept cold throughout the harvesting procedure. Cells 
were washed once with 1.5 ml cold PBS (containing protease inhibitor), scraped, and collected by 
centrifugation in pre-weighed 1.5 ml centrifuge tubes at 1,000 rpm for 5 minutes at 4°C.  The supernatant 
fluid was aspirated and then pelleted cells were lysed in cold buffer containing 62.5 mM Tris-HCl pH 6.5, 
2% SDS, 5% glycerol, 5% 2-mercaptoethanol, 50 mM NaF, and a 1X concentration of Complete EDTA-
free Protease Inhibitor Cocktail.  Lysates were sonicated on high power for 7.5 minutes at 30 seconds on, 
30 seconds off intervals in a Diagenode Bioruptor bath sonicator and then were centrifuged at 14,000 rpm 
for 5 minutes.  
Protein Concentration Assays: The Bradford Assay was used to determine protein concentration of each 
sample using the Bradford Reagent according to the manufacturer’s protocol with BSA as a standard. 
Duplicate assays were conducted for each sample as well as for the standard curve. Standard curve 
samples contained 699-799μl of H2O at 20μl intervals, 1μl of SDS lysis buffer and BSA (0-10μg) while 
sample tubes contained 799μl of H2O and 1μl of protein extract. Bio-Rad dye concentrate (Cat # 500-
0006) (200μl) was added to each tube. After 15 minutes incubation at room temperature, absorbance was 
determined using a spectrophotometer at 595nm wavelength. Typically, protein concentrations were 2-5 
μg/μl.  Protein was placed in single-use aliquots and stored at -80°C.  
SDS-PAGE and Protein Transfer: Gel electrophoresis and wet membrane transfers were performed 
using the Mini PROTEAN-3 Cell system (Cat #1653301) from Bio-Rad Laboratories. Total protein was 
mixed with an equal volume of Laemmli Sample Buffer, boiled for 5 minutes, and 20 μg was loaded onto 
1.5 mm SDS-polyacrylamide gels, poured according to the recipe provided with 30% Acrylamide/Bis 
37:5:1 (Cat #1610158) from Bio-Rad Laboratories. An aliquot (5-10 μl) of Dual Color Precision Plus 
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Protein Standard was also loaded onto every gel for mass determination. Typically, protein was resolved 
on 7.5% or 12% gels in running buffer (25 mM Tris base, 250 mM glycine, 0.1% SDS) at 50 volts for 30 
minutes (or until protein migrated out of the stacking gel) followed by 120 volts for 1-1.5 hours to 
optimally separate the proteins of interest.  
After electrophoresis, the gel was washed in water then transferred to a PVDF membrane that was pre-
washed in 100% methanol. Transfer was performed in ice bath with stir bar placed in transfer apparatus 
for 60 minutes at 100 volts in 1X Transfer Buffer (25mM Tris-HCl, pH 8.3, 192mM glycine, 10% 
methanol and 0.04% SDS). Following the transfer, membranes were dipped in methanol and dried on the 
lab bench for 15 minutes before being immunoblotted. 
Antibody Detection: A general antibody detection procedure is described in this section. For detailed 
conditions for each antibody, refer to Table 1. Dried membranes were soaked briefly in methanol and 
non-specific proteins were blocked for 1 hour in either StartingBlock Blocking Buffer. Membranes were 
washed three times for 5 minutes in 0.1% TBS-T (25mM Tris-HCl, pH 8.3, 192mM glycine, 0.04% SDS, 
0.1% Tween-20). Primary antibodies diluted in StartingBlock Buffer were incubated on the membranes 
overnight at 4°C with rotation in sealed plastic containers to minimize antibody consumption. Membranes 
were washed 3 times with 0.1% TBS-T for 5 minutes and incubated for 1 hour in horseradish peroxidase-
conjugated secondary antibody. After incubation, three 10 minute washes in 1X TBS-T were performed. 
It was found that washing more stringently during this step greatly diminished non-specific background 
during exposure. Membranes were incubated with West Pico (Pierce, Cat# 34080) or West Dura 
SuperSignal chemiluminescence substrate (Pierce, Cat# 34075) for 5 minutes. Blots were developed using 
ODYSSEY LI-COR imager (LI-COR Biosciences, Nebraska, USA) using 700 nm and 
chemiluminescence channels. If the chemiluminescent conditions were not known, West Pico was applied 
first. If no signal was apparent, the blot was rinsed with 0.1% TBS-T, and West Dura solution was 
applied. Signal was usually observed with one of these conditions, and rarely was a more stringent 
detection reagent applied.  
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Table 1: List of antibodies used for western blotting 
Antigen 
Primary Ab 
obtained 
from 
Primary 
Ab 
Dilution 
Blocking 
Buffer 
Secondary 
Ab Used 
Secondary 
Ab 
Dilution 
Expected 
protein 
band size 
Chemiluminescent 
substrate prepared 
p70-S6K1 
Cell 
Signaling 
Cat. 9202S 
1:1000 Starting 
Block 
Goat Anti-
Rabbit 
1:5000 
70 kD Dura 
P – p70-
S6K1 
Cell 
Signaling 
Cat. 9205L 
1:500 Starting 
Block 
Goat Anti-
Rabbit 
1:5000 70 kD 
Dura 
4E-
BP1(53H11) 
Cell 
Signaling 
Cat. 9644P 
1:1000 Starting 
Block 
Goat Anti-
Rabbit 
1:5000 15-20 kD 
Pico 
P-4E-
BP1(T37/46) 
Cell 
Signaling 
Cat. 2855L 
1:1000 Starting 
Block 
Goat Anti-
Rabbit 
1:5000 15-20 kD 
Dura 
eIF4E 
(C4SH6) 
Cell 
Signaling 
Cat. 2067S 
1:1000 Starting 
Block 
Goat Anti- 
Rabbit 
1:5000 70 kD 
Dura 
β - Actin 
Cell 
Signaling 
Cat. 3700S 
1:5000 Starting 
Block 
Goat Anti-
Mouse 
1:5000 42 kD 
Pico 
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2.7 m7GTP capture of 4E-BP1-eIF4E complexes 
 
Following the indicated drug treatments, cells were lysed on ice for 30 minutes in IP buffer [25 mmol/L 
of HEPES (pH 7.5), 1% NP40, 100 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 50 mmol/L NaF, 
1 mmol/L phenylmethylsulfonylfluoride, 0.1% 2-mercaptoethanol, and 1X Roche Complete Protease 
Inhibitor Tablet]. An aliquot (500 mg) of cleared lysate was incubated with 40 mL of 50% slurry of 
m7GTP-Sepharose (GE Lifesciences) for 2 hours at 4°C with rotation. m7GTP captured complexes were 
washed with IP buffer 4 times, resuspended in Laemmli sample buffer, and boiled for 5 minutes before 
being resolved on a 12.5% SDS-PAGE gel and immunoblotted as described above. 
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Chapter 3: Results 
 
3.1  Pemetrexed and AICAR inhibit the proliferation of human NSCLC cells 
 
As mentioned in section 1.2, Ding et al (2008) have shown that tumor suppressor genes p53, CDKN2A 
and STK11, and several oncogenes KRAS and EGFR are most frequently mutated in lung cancers. We 
examined the anti-proliferative effects of the AMPK activators, PTX and AICAR, in three NSCLC cell 
lines that differ in the mutational status of the KRAS and/or p53 genes. The cell lines were H661, which 
had a mutation in p53 and p16 genes, H441, which had a mutation in p53 and KRAS genes, and H358, in 
which the p53 gene was lost and the KRAS gene was mutated. The specific genotype of each cell line can 
be found in Table 2. Each of these cell lines was plated in 12-well plates (3.9 cm
2
/well), allowed to adhere 
over 48 hours, and then continuously exposed to increasing concentrations of drug over 72 hours. Cell 
growth was plotted as a percent of control growth. Following PTX or AICAR treatment, the cell growth 
rate was suppressed in all three cell lines in a dose-dependent manner (Figure 8 and Figure 9). H661 and 
H358 were equi-sensitive to AICAR and H441 was, on the average, 3-fold less sensitive. Complete 
suppression of cell growth required AICAR concentrations ≥ 1 mM. The cell lines that differed 
dramatically in genotype (Table 3) demonstrated minimal difference in sensitivity to AICAR.  On the 
other hand, H441 and H358 exhibited equal sensitivity to PTX and the growth of these cell lines was 
suppressed at lower concentrations than the H661 cell line. Although, H661 showed dose-dependent 
growth inhibition, the effect plateaued off at high doses of PTX. PTX was substantially more potent than 
AICAR with IC50 values 100-1000 times lower for these cell lines. H441 and H358 cells have mutations 
(or deletions) in both the p53 and KRAS genes. H661, in addition to a mutation in p53, has a mutation in 
the p16 gene (also known as CDKN2A), which is a tumor suppressor gene plays an important role in cell 
cycle regulation (Stone et al. 1995) (see discussion). Interestingly, a recent publication reported that 
NSCLC cell lines with mutant KRAS gene were, as a class, measurably more sensitive to PTX than 
NSCLC lines with wild type  
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Table 2: Partial genotype of the NSCLC cell lines used in these studies. 
Genes 
Cell line      p53 KRAS p16 
H661 R158L wt C457+1G>T 
H441 R158L G12V wt 
H358 null G12C wt 
 
 Mutation status of p53, KRAS, and p16 in each cell line was determined from the Sanger 
Catalogue of Somatic Mutations in Cancer database (COSMIC; 
http://www.sanger.ac.uk/genetics/CGP/cosmic) 
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Figure 8: Growth suppression of NSCLC cells in the presence of AMPK activators AICAR (A) and 
pemetrexed (B). Cells were treated with indicated drugs for 72 hours and the number of cells per well 
was measured using a Beckman Coulter counter. 
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Figure 9: Growth suppression of NSCLC cells in the presence of AMPK activators AICAR (A) and 
pemetrexed (B). Cells were treated with indicated drugs for 72 hours and the number of cells per well 
was measured using a Beckman Coulter counter. 
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KRAS (Moran et al. 2014). These experiments demonstrated that PTX and AICAR dose-dependently 
inhibited the growth of NSCLC cells in vitro. 
3.2  NSCLC cells showed differential sensitivity to PTX in the presence and 
absence of thymidine 
 
The primary target of PTX and its metabolites was originally shown to be thymidylate synthase (TS; 
Taylor et al. 1992, Hsieh et al. 1998). Recently, it was discovered in our laboratory that PTX also acts on 
a secondary target AICART, the second folate dependent enzyme of de novo purine synthesis (Racanelli 
et al. 2009, Rothbart et al. 2010). The inhibition of purine synthesis resulted in the accumulation of ZMP 
which, in turn, causes a marked activation of AMPK (Racanelli et al. 2009, Rothbart et al. 2010). To 
separate the effects of these two mechanisms of PTX, we circumvented the action of PTX on TS to allow 
us to study its effect only on AMPK activation. Hence, we performed growth inhibition assays with PTX 
in the presence and absence of 5.6 µmol/L thymidine, a salvageable source of thymidylate that reverses 
the effects of TS inhibition by PTX. As expected, PTX in the absence of thymidine, the condition that 
displays the growth inhibitory effect of both TS and AICART, was much potent than in the presence of 
thymidine, which reflects only AICART inhibition. The H441 cell line, in which p53 and KRAS are both 
mutated, showed the highest difference in sensitivity for PTX with and without thymidine, with a 40-fold 
decrease in IC50 in the absence of thymidine. A marked difference in sensitivity for PTX with and without 
the addition of thymidine was also observed with H358 cell line (p53 null, KRAS mutant) with 
approximately 10-fold decrease in IC50 of PTX when thymidine was not added to the media.  H661, in 
which KRAS was wild type showed the least difference in sensitivity for PTX – alone or with thymidine, 
and we were unable to obtain IC50 values in the presence of thymidine even at very high concentration 
(10 µM) of PTX used. We concluded that the H661 cell line was relatively refractory to PTX. These 
experiments did not shed any light on why the response of these cell lines to PTX was so markedly  
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Figure 10:Growth suppression effects of PTX in the presence and absence of Thymidine on NSCLC 
cell lines A)H441, B)H661 and C)H358. NSCLC cells were treated PTX, in the presence and absence of 
thymidine for 72 hours and the number of cells per well was measured using a Beckman Coulter counter.  
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different. Whether the existence of a p16 mutation in this cell line was involved was interesting to 
consider, but more studies are required to understand these effects. 
3.3  Inhibition of mTORC1 and mTORC2 is more detrimental to cell growth 
and proliferation than inhibition of mTORC1 alone 
 
Rapamycin was the first drug discovered to inhibit the mammalian target of rapamycin (mTOR) protein. 
The rapamycin analog, RAD001 acts by the same molecular mechanism as rapamycin to allosterically 
inhibit mTORC1 and is currently approved for the treatment of renal cell carcinoma. We evaluated the 
efficacy of RAD001 as an inhibitor of cell growth in NSCLC cell lines. It was observed that RAD001 did 
decrease cell growth but that the dose response curves were extremely shallow (Figure 11). This came 
across as an interesting fact as previous studies have shown that RAD001 at concentrations of 5-20 nM 
completely inhibit mTORC1 activity. RAD001 is used clinically for the treatment of renal cancer and 
plasma concentrations only reach 5 – 20 nM. Yet, even at a 100-fold (2000 nM) greater concentration 
than what is used clinically, it was not possible to obtain an IC50 value in the H661 and h441 cells 
suggesting that RAD001 would be a poor drug to inhibit proliferation of NSCLC cells with these 
genotypes. RAD001 is directed towards only mTORC1 inhibition without any effect on mTORC2 and 
also results in release of feedback control of Akt activity. This may suggest that the reduced efficacy of 
RAD001 is due to an incomplete block of mTOR signaling and hence, cell growth. In order to overcome 
this problem and inhibit mTORC2 mediated feedback loops that reduce the efficacy of rapalogs, we used 
a dual mTORC1/2 inhibitor AZD8055 (Figure 12). AZD8055 demonstrated greater efficacy and potency 
over RAD001 in suppressing growth of cells. All three NSCLC cell lines were equi-sensitive to 
AZD8055 and exhibited IC50s in the range of 80 – 120 nM. This comparison furnishes direct evidence 
that inhibition of both mTORC1 and mTORC2 is more beneficial in controlling cell survival and growth 
than is inhibition of mTORC1 alone. 
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Figure 11: Growth suppression of NSCLC cells in the presence of mTORC1 inhibitor RAD001. 
Cells were treated with indicated drugs for 72 hours and the number of cells per well was measured using 
a Beckman Coulter counter. 
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Figure 12: Growth suppression of NSCLC cells in the presence of dual mTORC1/2 inhibitor 
AZD8055. Cells were treated with indicated drugs for 72 hours and the number of cells per well was 
measured using a Beckman Coulter counter. 
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3.4  Combination of AZD8055 with AMPK activators AICAR and Pemetrexed 
showed superior anti-proliferative effects than either drug alone 
 
3.4.1 AICAR enhances the effects of AZD8055 and vice-versa 
 
We demonstrated that both AICAR and PTX were able to suppress the growth of NSCLC cells. In 
addition, AZD8055 was superior to RAD001 in terms of growth inhibitory effects. Hence, we tested the 
effects of combination of AICAR or PTX with AZD8055 on cell growth and proliferation. Because the 
H358 cell line has shown intermediate differences in sensitivity to PTX in the presence and absence of 
thymidine and grew reproducibly well in culture, we decided to perform detailed drug interaction studies 
on this cell line. The main aim of this project is to evaluate combinations of mTOR antagonists and PTX; 
hence, using a cell line that shows intermediate differential sensitivity to PTX indicated the most 
representative sensitivity of the two targets of this drug, namely TS and AMPK. On combining AICAR 
and AZD8055, we saw that the dose-response curve of one drug was not shifted to the left with the 
addition of lower increments of the other drug, but at concentrations on the range of an IC50 of one drug, 
the dose-response curve was substantially shifted (Figure 13). The IC50 of AICAR was reduced by 
approximately 5-fold with the addition of 64 nM AZD8055. Similarly, the addition of 100 µM AICAR 
reduced the IC50 of AZD8055 by 10-fold. This suggested that addition of an AMPK activator enhanced 
the growth inhibitory effects of an mTOR inhibitor and vice-versa. Thus, these data were analyzed for 
fractional IC50 and plotted as an isobologram (Figure 14). This analysis indicated an additive combined 
effect on tumor cell growth. 
3.4.2 Pemetrexed enhances the effects of AZD8055 and vice-versa 
 
Following the effects seen with combinations of AICAR and AZD8055, we performed a similar 
experiment with AZD8055 and an US FDA approved drug for NSCLC, pemetrexed. In order to reverse 
the effects of PTX on TS, this experiment was carried out in the presence of 5.6 µM thymidine. As also  
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Figure 13: Enhancement of growth suppression effects of AICAR in combination with AZD8055 
and vice-versa. Leftward shifts in the IC50 in the Concentration-Effect curves of A) AICAR in the 
presence of AZD8055 dose increments and B) AZD8055 in the presence of AICAR dose increments. 
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Figure 14: Isobologram of additivity for AICAR+AZD8055. The combination of AICAR+AZD8055 
was found to be additive, when normalized data points from the growth suppression assay of 
AICAR+AZD8055 were plotted on the isobologram. 
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(B) 
Figure 15: Enhancement of growth suppression effects of pemetrexed in the presence of thymidine, 
in combination with AZD8055 and vice-versa. Leftward shifts in the IC50 in the Concentration-Effect 
curves of A) PTX in the presence of AZD8055 dose increments and B) AZD8055 in the presence of PTX 
dose increments. 
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Figure 16: Isobologram of additivity for PTX+AZD8055, in the presence of thymidine. The 
combination of PTX+AZD8055 in the presence of thymidine was found to be highly synergistic, when 
normalized data points from the growth suppression assay of PTX+AZD8055 (+ thymidine) were plotted 
on the isobologram. 
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seen in figure 10,  we observed that PTX by itself showed a dose-dependent decrease in cell growth of 
H358 cells in the presence of thymidine at an IC50 of ~ 300 nM. The addition of a small amount (10 nM) 
of the catalytic site mTORC1/2 inhibitor reduced the IC50 to ~ 200 nM, with a further decrease in IC50 of 
PTX seen with addition of 32 nM AZD8055 (Figure 15A). This reduction in IC50 was approximately 8-10 
folds, which is very promising in terms of cancer therapeutics. Further addition of AZD8055 to PTX 
reduced the IC50 even more, suggesting that AZD8055 enhanced the effects of PTX in inhibiting growth 
and proliferation of H358 cells. When the data was plotted in the reverse manner to evaluate the benefit of 
adding PTX to AZD8055, we observed a similar phenomenon. AZD8055 by itself suppressed growth of 
cells very efficiently at an IC50 of ~ 120 nM. However, addition of small increments of PTX 
progressively shifted the dose- response curve of AZD8055 to the left (Figure 15B), demonstrating a 
reduction in the IC50 of AZD8055 and suggesting that each drug enhanced the growth inhibitory effects 
of other when co-administered. The isobologram constructed to summarize this combination indicated a 
strongly synergistic interaction (Figure 16). 
3.4.3 Pemetrexed combined with AZD8055 results in enhanced antitumor efficacy in the absence 
of thymidine 
 
To determine the utility of PTX and AZD8055 combination in clinically relevant conditions, we 
performed the aforementioned combination experiment of PTX and AZD8055 without adding 5.6 µM 
thymidine to the media. Under such conditions, PTX acts as an inhibitor of AICART, as an activator of 
AMPK, as well as an inhibitor of TS and is more substantially potent than in the presence of thymidine, 
when it is an AICART inhibitor and activator of AMPK alone. In the absence of thymidine, PTX 
demonstrated more than a 5-fold greater potency at suppressing growth of H358 cells than that in the 
presence of thymidine (Figure 10). The IC50 observed for PTX by itself was approximately 32 nM with a 
sharp dose- response curve (Figure 17A). In addition to the superior potency observed of PTX by itself, 
addition of AZD8055 to PTX further shifted the IC50 of PTX towards the left indicating that addition of a  
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Figure 17: Enhancement of growth suppression effects of pemetrexed in the absence of thymidine, 
in combination with AZD8055 and vice-versa. Leftward shifts in the IC50 in the Concentration-Effect 
curves of A) PTX in the presence of AZD8055 dose increments and B) AZD8055 in the presence of PTX 
dose increments. 
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Figure 18: Isobologram of additivity for PTX+AZD8055, in the absence of thymidine. The 
combination of PTX+AZD8055 was found to be mildly synergistic to additive, when normalized data 
points from the growth suppression assay of PTX+AZD8055 were plotted on the isobologram. 
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Table 3: IC50 concentrations of H358, H441 and H661 for PTX, AICAR, AZD8055 and RAD001. 
IC50 values (µM) 
Treatment H358 H661 H441 
AICAR 139;  100;  120;  90 139 320 
PTX +Tdr 0.29, 0.2;  0.3;  0.32 > 2 2 
PTX -Tdr  0.03, 0.029, 0.03, 0.039 > 2 0.04, 0.05, 0.007 
AZD8055 0.09;  0.08;  0.2;  0.09 0.13 0.11 
RAD001 > 1 , > 1 > 3, > 3 > 3, > 3 
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direct mTOR inhibitor with PTX treatment has even greater benefits in reducing tumor cell growth. 
Similar to what was seen in the presence of thymidine, when the same data were plotted as a function of 
AZD8055 dose- response, incremental additions of PTX enhanced the anti-proliferative potential of 
AZD8055 with significant shifts of the dose-response curves to the left (Figure 17B). The data were 
analyzed for fractional IC50 and plotted as an isobologram (Figure 18). This isobologram indicated a 
somewhat synergistic pattern, but significantly less than seen in the presence of thymidine. Hence, from 
the growth suppression studies conducted so far, it can be concluded that the combination of AMPK 
activators (PTX or AICAR) with ATP-site dual mTOR inhibitor AZD8055 exhibits greater anti-tumor 
efficacy over either monotherapy. 
3.5  Dual blockade of PI3K/Akt/mTOR and LKB1/AMPK/mTOR pathway is 
synergistic or additive in NSCLC cell lines 
 
An isobologram is a graphical representation of drug interactions and is considered by many investigators 
to be the “gold standard” for the assessment of drug combinations. In order to confirm whether any of the 
drug combinations we had used had anti-tumor efficacy than expected from that of the individual drugs, 
isobolograms were constructed using normalized IC50 values as described in section 2.5.2 and were 
examined for synergy, antagonism, and additivity in H358 cells. We observed that in the combination of 
AICAR and AZD8055, data points were scattered near the line of additivity on both sides and that the 
interaction was clearly additive in NSCLC H358 cell line (Figure 14). Upon plotting the data of Figures 
15A and 15B as an isobologram (Figure 16), the combination of PTX and AZD8055 in the presence of 
5.6 uM thymidine was found to be highly synergistic with all data points lying in the zone of the 
isobologram substantially below the line of additivity. A comparison of the isobolograms in figures 14 
and 16 displays a strikingly different outcome. This was very surprising in view of the hypothesis that 
both PTX in the presence of thymidine and AICAR were thought to have the same mechanism, namely 
activation of AMPK (see Discussion). When the data points from the experiment of PTX and AZD8055 
combination in the absence of thymidine (Figures 17A and 17B) were constructed into an isobologram 
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(Figure 18), they demonstrated a slightly synergistic to additive effect over the curve. This indicated that 
the interaction of PTX in the presence of thymidine, in combination with AZD8055 showed superior drug 
interaction as compared to PTX as a dual inhibitor of AICART and TS. We think that this might be 
because PTX in the absence of thymidine is potent by itself, and shows more than 5-fold lower IC50 than 
PTX plus thymidine (see Discussion).  
3.6  Pemetrexed and AZD8055 both inhibit mTOR signaling 
 
In an effort to explain the synergistic interaction observed with pemetrexed and AZD8055 on H358 cells,  
mTOR kinase inhibiton by pemetrexed and AZD8055 was assessed in intact H358 cells (Figure 19). 
Initially, phosphorylation of S6K1 was measured by western blotting. S6K1 is a direct downstream target 
of mTORC1 which plays a  critical role in cap-dependent translation (Figure 2). Phosphorylation of S6K1 
activates its kinase activity which then converts ribosomal protein S6 to its phosphorylated form, a 
necessary step in its recruitment of the components of the cap-dependent translational preinitiation 
complex. It was observed that pemetrexed decreased the phosphorylation of S6K1 at T389, in the 
presence and absence of thymidine, when compared to untreated cells; however, the hypophosphorylation 
of S6K1 was markedly greater with pemetrexed in the absence of thymidine and was thought to occur 
because of its effect on AICART as well as thymidylate synthase. AZD8055 is a potent inhibitor of both 
mTORC1 and mTORC2 and inhibited phosphorylation of S6K1 to much gretaer extent than pemetrexed. 
3.7  Effects of combining pemetrexed in the presence of thymidine and 
AZD8055 
 
In order to examine the effects of pemetrexed and AZD8055 in combination on mTOR inhibition, we 
tested them at 0.5, 1, and 2 X IC50 concentrations alone and in combination with the other drug. These  
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Fig 19: Effects of pemetrexed and AZD8055 on phosphorylation of S6K1 following mTORC1 
inhibition. 
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experiments, then, tested whether the effects of these drugs on mTORC1/2 correlated with the early 
stages of growth inhibition and, therefore, could be said to be causative of the growth suppression. The 
concentrations of pemetrexed used were 160, 320, and 640 nM; and AZD8055 was used at concentrations 
61.25, 125, and 250 nM. It was observed that pemetrexed (lanes 3,4, and 5; Figure 20A and 20B) dose 
dependently inhibited the phosphorylation of S6K1 as compared to untreated cells, with highest inhibition 
observed at 2X IC50 concentration. Pemetrexed also inhibited phosphorylation of another mTORC1 
substrate 4E-BP1 dose-dependently. 4E-BP1, like S6K1, plays a critical role in cap-dependent translation. 
It inhibits cap-dependent mRNA translation by binding and inactivating eukaryotic translation initiation 
factor 4E (eIF4E) that is involved in the mRNA-ribosome binding step of eukaryotic protein synthesis. 
Phosphorylated 4E-BP1 by mTOR is dissociated from eIF4E, resulting in increasing protein synthesis. 
Thus, hypophosphorylation of 4E-BP1 by mTOR inhibition would lead to 4E-BP1 not dissociating from 
eIF4E resulting in inhibition of protein synthesis and cell proliferation. 4E-BP1 can be separated into 
hypo and hyperphosphorylated bands using a 12% gel, with the unphosphorylated form at the bottom and 
hyperphosphorylated forms preogressively higher in the gel. It was seen that pemetrexed decreased the 
levels of total 4E-BP1 as compared to control (Fig 20 B) but there was no dose-dependent effect apparent. 
However, the intensity of darkness shifted from more phosphorylated forms down to the less 
phosphorylated form with greater hypophosphorylation observed at highest pemetrexed concentration 
(640 nM) (Fig 20A). Unphosphorylated 4E-BP1 is known to tightly bind to eIF4E-capped mRNA 
complexes, preventing the binding of eIF4G and the initiation of cap-dependent translation, so we 
measured the binding of 4E-BP1 to eIF4E-cap complexes in extracts of drug-treated cells. The binding of 
4E-BP1 to eIF4E-bound 7-methylGTP-beads was enhanced by pemetrexed and the hypophosphorylated 
form that was predominant at the highest concentration of pemetrexed (Fig. 20B), indicating that 
pemetrexed inhibited initiation of cap-dependent translation. Taken together, it was observed that 
pemetrexed was able to inhibit mTOR signaling as evident from inhibition of mTOR substrates S6K1  
and 4E-BP1. 
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AZD8055 (lanes 6, 7, and 8; Figure 20A and 20B) was much more potent than pemetrexed at inhibition 
of the phosphorylation of S6K1 and of 4E-BP1 at fractional concentrations of its IC50. AZD8055 
demonstrated very high potency at hypophosphorylating both the substrates even at 0.5X IC50 with a 
tremendous inhibitory effect at higher concentrations. The levels of total 4E-BP1 were dose-dependently 
reduced with the hypophosphorylated form predominant at higher concentrations (Figure 20A and 20B). 
On assessing the levels of 4E-BP1–eIF4E-7mGTP-bound capped complexes, a significant enhancement 
was seen with AZD8055 treatment which increased in intensity with increase in dose of AZD8055. It 
suggested that AZD8055 was more efficient than pemetrexed in inhibiting mTOR kinase. 
When pemetrexed at an IC50 concentration was combined with fractional IC50 concentrations of 
AZD8055 (lanes 9, 10, and 11; Figure 20A and 20B), the phosphoryaltion of S6K1 was substantially 
lower as compared to untreated and pemetrexed IC50-treated cells, but the effect was not consistent over 
graded IC50 concentrations of AZD8055. Similarly, phosphorylation of 4E-BP1 by a combinaiton of 
AZD8055 and PTX was decreased compared to control and pemetrexed alone at their IC50s. However, 
addition of pemetrexed IC50 to fractional IC50s of AZD8055 did not have any benefit over the individual 
fractional IC50s of AZD8055 in inhibiting phosphorylation of 4E-BP1. If any, there was increase in 
phosphorylation seen in lanes 10 and 11 compared to lanes 7 and 8. Total 4E-BP1 levels were decreased 
compared to untreated cells, but no significant difference was observed over lane 4 and lanes 6, 7, and 8. 
However, there was an apparent increase in hypophosphorylated form in lane 11 over lane 4 and lane 8 
suggested that phosphorylation was decreased with the combination. The 4E-BP1–eIF4E-7mGTP-bound 
capped complex levels showed a decrease initially (compare lane 9 and lane 10) but it gradually increased 
with increase in dose (compare lane 10 and 11). This data indicated that addition of IC50 dose of 
pemetrexed to AZD8055 did not have any major benefit over AZD8055 as a single agent on inhibition of 
mTORC1. 
On the other hand, when IC50 dose of AZD8055 was added to fractional IC50s of pemetrexed (lanes 12, 
13, and 14), phosphorylation of S6K1 was inhibited much greater than with either drug alone. On the  
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Figure 20 A: mTOR signaling events following treatments with pemetrexed (+ thymidine) and 
AZD8055, experiment 1. 
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Figure 20 B: mTOR signaling events following treatments with pemetrexed (+ thymidine) and 
AZD8055, experiment 2. 
 
 
 
 
 
59 
 
contrary, though phopho-4E-BP1 levels were lower with concentrations of both drugs than seen at 
equivalent pemetrexed fractional IC50s (compare lanes 12, 13 and 14 to lanes 3, 4, and 5 respectively), 
they were increased when compared to AZD8055 IC50s (compare lanes 12, 13 and 14 to lane 7). Total 
4E-BP1 levels showed a decrease with the combination over individual drugs with the unphosphorylated 
form predominant. The 4E-BP1–eIF4E-7mGTP-bound capped complex levels demonstrated highest 
levels with the combination of drugs.  
Taken together, we concluded that pemetrexed ad AZD8055 exhibited inhibition of mTOR as individual 
drugs, but this inhibtion was greater with the combination of these two drugs. However, it looks like 
much of the inhibitory effects of the combination on mTORC1 are mediated by AZD8055 and 
pemetrexed does not add much to the combination with regards to inhibtion of mTORC1. The ability of 
AZD8055 to completely inhibit mTOR at both the complexes might explain this potency of AZD8055. 
3.8  Effects of combining pemetrexed and AZD8055, in the absence of 
thymidine 
 
In order to study the effects of pemetrexed in clinically relevant conditions, the aforementioned 
experiment was conducted in the absence of thymidine (Figure 21). AZD8055 was used at the 
concentrations mentioned in section 3.5. For pemetrexed, in the absence of thymidine, it is more potent 
and exhibts an IC50 in the range of 40 – 50 nM. Hence the concentrations used for pemetrexed were 25, 
50 and 100 nM. It was seen that, with these concentrations which were more than 5-fold lower than those 
used in the presence of thymidine, pemetrexed (lanes 2, 3, and 4) inhibited phosphorylation of S6K1 
much more. Unlike the experiment using PTX and thymidine, levels of total S6K1 were greatly inhibited 
by these concentrations of pemetrexed. It was also apparent that phosphorylation of 4E-BP1 and levels of 
total 4E-BP1 were significantly reduced under pemetrexed treatment and the reduction was dose- 
dependent. As observed with this combination in the presence of thymidine, the 4E-BP1 bands shifted 
towards the hypophosphorylated form at 100 nM pemetrexed, indicating that phosphorylation was  
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Figure 21: mTOR signaling events following treatments with pemetrexed and AZD8055, in the 
absence of thymidine. 
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reduced. AZD8055 (lanes 5, 6, and 7) demonstrated dose-dependent decrease in the levels of phopho and 
total S6K1; while p-4E-BP1 levels increased with 0.5 and 1X IC50 of AZD8055 (lanes 5 and 6; p-4E-
BP1), they decreased with further increment in dose. Total 4E-BP1 showed a dose-dependent decrease 
with a predominance of the hypophosphorylated form at increasing AZD8055, suggesting that 
phosphorylation was inhibited. The addition of IC50 concentrations of pemetrexed to fractional IC50 
concentrations of AZD8055 (lanes 8, 9, and 10) did not show any superior effects over fractional IC50s of 
AZD8055 alone (compare lanes 8, 9, and 10 to lanes 5, 6, and 7). But, when IC50 of AZD8055 was added 
to fractional IC50s of pemetrexed (lanes 11, 12, and 13), the effects on phosphorylation events of both 
S6K1 and 4e-bp1 was significantly higher with pemetrexed alone (compare lanes 11, 12, and 13 to lanes 
2, 3, and 4). The difference in levels of total S6K1 was apparent also, but no difference was observed for 
total 4E-BP1 levels. From this experiment, it was evident that pemetrexed in the absence of thymidine 
was much more potent as an inhibitor of mTORC1 than in the presence of thymidine, with low nanomolar 
concentrations sufficient to inhibit mTORC1 kinase activity. AZD8055 was always superior to 
pemetrexed in inhibiting mTOR function. The combination treatments did not show any significant 
differences from AZD8055 as a single drug, but they were different from pemetrexed as a single drug. It 
can be concluded that most of the effects of the combination treatment on mTORC1 activity were 
mediated via AZD8055 in the absence of thymidine similar to what was seen in thymidine-containing 
medium. 
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Chapter 4: Discussion 
 
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) acts as a sensor of energy status and 
modulates cellular functions that drive cell growth and proliferation. mTOR is the target of rapamycin 
which was initially discovered as a macrolide antibiotic but gained attention because of its 
antiproliferative properties. mTOR regulates protein synthesis via S6K1 and 4E-BP1, and dysregulation 
of mTOR signaling is seen in most cancers. It has been shown that activated AMPK directly inhibits 
mTORC1 kinase endogenously by TSC2 and raptor phosphorylation (Gwinn et al. 2008, Inoki et al. 
2003). mTOR, an integral protein of the mTOR signaling pathway responds to intracellular and 
extracellular signals to serve as a central regulator of cell metabolism, growth, proliferation and survival. 
Alterations in these pathways can contribute to human disease states, including cancer (Calkhoven et al. 
2002). AMPK is activated by the antidiabetic drug metformin (Hardie 2011), and it was observed that 
diabetics on metformin therapy had lower incidence of cancer than those on other anti-diabetic agents 
(Lin et al. 2014). Thus, it was evident that regulation of AMPK and mTOR are of importance with respect 
to cell survival and metabolism, and alterations in this pathway could predispose organisms to cancer. 
The purpose of this dissertation was to determine the interactions of activation of AMPK and direct 
pharmacological inhibition of mTOR and how the combined effect suppresses NSCLC cell proliferation.  
AICAR is a classical activator of AMPK. It gets converted to ZMP and mimics AMP to activate AMPK 
(Hardie 2011). Pemetrexed is an antifolate used for the treatment of NSCLC. Recently, our laboratory 
reported that pemetrexed, in addition to inhibition of TS, inhibited a second folate-dependent enzyme of 
de novo purine synthesis, AICART, leading to AMPK activation and subsequent mTORC1 inhibition. To 
address our hypothesis, we combined the activators of AMPK, AICAR and/or pemetrexed, with dual 
mTORC1/2 inhibitor AZD8055 to determine the combined effects on cell growth and proliferation. 
Rapamycin and its analogs are strong inhibitors of mTORC1; hence we evaluated the efficacy of a 
rapamycin analog RAD001 on H661, H441, and H358 cell lines. Growth suppression experiments with 
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RAD001 and AZD8055 revealed dramatic differences in efficacy of the compounds. It was observed that 
the ATP-site mTOR inhibitor AZD8055 demonstrated stronger growth suppression effects than the 
rapalog, RAD001 (Figure 11 and Figure 12). Due to the excellent growth inhibitory effects observed with 
AZD8055, we concentrated on combining AZD8055 with the AMPK activating drug pemetrexed. The 
effects of pemetrexed are altered by the presence or absence of thymidine. In the former case, pemetrexed 
effects are only directed towards inhibition of AICART and activation of AMPK. Addition of thymidine 
to the media provides a salvageable source of thymidine which prevents the cellular effects of TS 
inhibition by pemetrexed. In the latter, pemetrexed acts as an inhibitor of both AICART and TS and is 
more potent. When AZD8055 was combined with pemetrexed in the presence of thymidine, a striking 
synergism was observed in suppression of growth of H358 cells (Figure 16). This led to the hypothesis 
that activation of AMPK would enhance direct pharmacological inhibition of mTORC1. Surprisingly, 
when this hypothesis was tested using a classical activator of AMPK, AICAR, the drug interaction was 
found to be additive (Figure 14) implying that growth limiting effects of pemetrexed in the presence of 
thymidine appear to be more complex than just activation of AMPK and subsequent inhibition of 
mTORC1 signaling. 
The effects of combination of pemetrexed and AZD8055 on mTORC1 signaling were directly studied by 
immunoblotting. We observed that AZD8055 and pemetrexed, in the presence or absence of thymidine, 
each inhibited mTORC1 signaling as single agents evident by hypophosphorylations of mTORC1 
substrates S6K1 and 4E-BP1. It was clear that both, pemetrexed (+ thymidine) and AZD8055, and 
pemetrexed (- thymidine) and AZD8055 inhibited mTORC1 signaling events. This is of great importance 
clinically as pemetrexed without thymidine is the clinically relevant condition and under these conditions, 
pemetrexed in combination with AZD8055 showed excellent anti-proliferative effects. Additionally, 
AZD8055 demonstrated superior effects over pemetrexed in inhibiting phosphorylation of S6K1 and 4E-
BP1 implying that AZD8055 was more potent on mTORC1 inhibition than pemetrexed. This was 
interesting because the concentrations of both the drugs chosen were the same fractions of IC50 and 
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therefore, we were testing whether the effects on mTORC1 signaling were responsible for inhibiting 
growth of cells at the first active concentrations of drugs. From this analysis, it was clear that given the 
intensity of mTOR signaling inhibition when an IC50 concentration of AZD8055 was combined with 
fractional IC50s of pemetrexed, AZD8055 inhibited mTORC1 signaling to a greater level than 
pemetrexed. We reached  a conclusion that although AMPK activation in mTORC1 inhibition were 
involved in the effects of pemetrexed, other effects of this drug might well be involved in the most 
sensitive steps that lead to growth inhibition. This idea needs further investigation.  
During the course of this dissertation, several interesting observations were made whose basis was not 
evident. It was seen that the combination of pemetrexed and AZD8055, in the presence of thymidine 
exhibited prominent synergism, while in the absence of thymidine; the interaction of pemetrexed with 
AZD8055 demonstrated a much lower level of synergism and was nearly additive. Pemetrexed in the 
absence of thymidine is more potent than in the presence of thymidine, demonstrating more than a 6-fold 
lower IC50 concentration in H358 cells. Another notable observation was that pemetrexed in the absence 
of thymidine greatly inhibited phosphorylation of S6K1 and 4E-BP1 compared to that in the presence of 
thymidine. Moreover, it was also able to reduce the levels of total S6K1 and 4E-BP1 compared to that in 
the presence of thymidine. This was interesting because immunoblotting was performed at fractional IC50 
concentrations treatment meaning pemetrexed in the absence of thymidine was used at 6-fold lower 
concentrations than that in the presence of thymidine but showed greater inhibitory effects on mTORC1 
signaling. It was not clear why this was observed; however, it appears that pemetrexed activity on 
mTORC1 might involve other unknown mechanisms.  
Pemetrexed is an US FDA approved drug for the first-line treatment of NSCLC in combination with 
cisplatin (Scagliotti et al. 2008). Interestingly, we observed that the H441 and H358 cell lines which have 
mutations in the KRAS gene showed greater sensitivity to pemetrexed than the H661cell line in which 
KRAS was wild type. Recently, a study from another laboratory (Moran et al. 2014) has shown that 
NSCLC cell lines with mutant KRAS gene were measurably more sensitive to PTX than NSCLC lines 
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with wild type KRAS. They reported that KRAS-mutant NSCLC cell lines showed greater dependency on 
folate metabolism pathways compared with KRAS wild-type NSCLC cell lines. They also reported that, 
following antifolate treatment, there was a robust downregulation of KRAS mRNA expression in both 
KRAS-mutant and wild-type cells and total KRAS protein expression and KRAS activity were decreased 
in KRAS-mutant cells (Moran et al. 2014). This was consistent with our observation that differential 
sensitivity to pemetrexed was observed with H441 and H358, and H661 (Figure 13). This is very 
important in NSCLC chemotherapy as KRAS is one of the most frequently mutated genes in lung 
carcinomas (Ding et al. 2008). Furthermore, it was interesting to note that H661 cell line which was least 
sensitive to pemetrexed has a mutation in the p16 gene. p16 is a tumor suppressor gene important in cell 
cycle regulation. The pl6 protein inhibits CDK4/6 and thereby prevents phosphorylation of Rb and cell 
cycle progression. It has been shown that pl6 and Rb are members of a growth-regulatory pathway often 
inactivated during tumor progression. (Stone et al. 1995). This could be one of the other reasons for H661 
not being very sensitive to pemetrexed. 
This study tested a novel hypothesis of combining dual mTORC1/2 inhibitor AZD8055 with an AMPK 
activator pemetrexed. A recent study by Kawabata et al. (2014) showed that the combination of 
rapamycin and pemetrexed exhibited synergistic interaction on growth suppression of NSCLC cells with 
enhancement of mTOR inhibition. They also reported that rapamycin leads to a weak downregulation of 
endogenous expression of TS that they interpreted to confer increased response to pemetrexed (Kawabata 
et al. 2014). In that study, it also was important to note the mutational status of the NSCLC cell lines. The 
NSCLC cell lines that showed sensitivity to the combination of rapamycin and pemetrexed harbored 
mutations in the PIK3CA or PTEN genes. When the same study was conducted in NSCLC cells lacking 
these mutations, rapamycin did not enhance the efficacy of pemetrexed in these cell lines (Kawabata et al. 
2014). This was consistent with our findings that the rapamycin analog RAD001 (everolimus) did not 
exhibit strong potency in inhibiting the proliferation of H661, H441, and H358. None of these cell lines 
have mutations in the PIK3CA or PTEN genes. Additionally, Markova et al. (2011) have shown that 
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rapalogs may suppress the anti-tumor activity of pemetrexed by slowing cell cycle progression. Our 
results have revealed that combining a dual mTORC1/2 inhibitor AZD8055 with pemetrexed has a 
synergistic to near additive interaction on inhibition of proliferation of NSCLC cells and these effects are 
mediated by inhibition mTORC1 signaling. However, other effects of pemetrexed might play an 
important role in controlling cell growth and more studies are needed to examine this mechanism. 
Future studies should be directed towards understanding the mechanisms of cell kill by the combination 
of pemetrexed and AZD8055. It would be a good approach to evaluate the effects of this combination on 
basal levels of TS. Given that AZD8055 markedly inhibits mTORC1 signaling at lower concentrations, 
studies are needed to evaluate the effects of AZD8055 on mTORC2 substrate Akt and subsequent 
feedback on mTORC1. It has been shown that inhibition of mTOR kinase by AZD8055 relieves 
inhibition of receptor tyrosine kinases (RTK) via the IRS-1 feedback loop, leading to subsequent PI3K 
activation and rephosphorylation of Akt T308 sufficient to reactivate Akt activity and mTORC1 signaling 
(Rodrik-Outmezguine et al. 2011). Thus, effects of combining AZD8055 with RTK inhibitor Sorafenib 
should be considered.  
Collectively, our studies have revealed that the combination of pemetrexed and AZD8055 has a 
synergistic to near additive effect on growth suppression of NSCLC cells; these effects appear to be 
mediated via mTORC1 signaling. mTORC1 inhibition is more pronounced with AZD8055 suggesting 
that additional mechanisms of cell kill would exist with pemetrexed treatment that needs further 
investigation.  
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